88 research outputs found

    Classification of Movement and Inhibition Using a Hybrid BCI

    Get PDF
    Brain-computer interfaces (BCIs) are an emerging technology that are capable of turning brain electrical activity into commands for an external device. Motor imagery (MI)—when a person imagines a motion without executing it—is widely employed in BCI devices for motor control because of the endogenous origin of its neural control mechanisms, and the similarity in brain activation to actual movements. Challenges with translating a MI-BCI into a practical device used outside laboratories include the extensive training required, often due to poor user engagement and visual feedback response delays; poor user flexibility/freedom to time the execution/inhibition of their movements, and to control the movement type (right arm vs. left leg) and characteristics (reaching vs. grabbing); and high false positive rates of motion control. Solutions to improve sensorimotor activation and user performance of MI-BCIs have been explored. Virtual reality (VR) motor-execution tasks have replaced simpler visual feedback (smiling faces, arrows) and have solved this problem to an extent. Hybrid BCIs (hBCIs) implementing an additional control signal to MI have improved user control capabilities to a limited extent. These hBCIs either fail to allow the patients to gain asynchronous control of their movements, or have a high false positive rate. We propose an immersive VR environment which provides visual feedback that is both engaging and immediate, but also uniquely engages a different cognitive process in the patient that generates event-related potentials (ERPs). These ERPs provide a key executive function for the users to execute/inhibit movements. Additionally, we propose signal processing strategies and machine learning algorithms to move BCIs toward developing long-term signal stability in patients with distinctive brain signals and capabilities to control motor signals. The hBCI itself and the VR environment we propose would help to move BCI technology outside laboratory environments for motor rehabilitation in hospitals, and potentially for controlling a prosthetic

    MicroRNA Expression Characterizes Oligometastasis(es)

    Get PDF
    Cancer staging and treatment presumes a division into localized or metastatic disease. We proposed an intermediate state defined by ≤ 5 cumulative metastasis(es), termed oligometastases. In contrast to widespread polymetastases, oligometastatic patients may benefit from metastasis-directed local treatments. However, many patients who initially present with oligometastases progress to polymetastases. Predictors of progression could improve patient selection for metastasis-directed therapy.Here, we identified patterns of microRNA expression of tumor samples from oligometastatic patients treated with high-dose radiotherapy.Patients who failed to develop polymetastases are characterized by unique prioritized features of a microRNA classifier that includes the microRNA-200 family. We created an oligometastatic-polymetastatic xenograft model in which the patient-derived microRNAs discriminated between the two metastatic outcomes. MicroRNA-200c enhancement in an oligometastatic cell line resulted in polymetastatic progression.These results demonstrate a biological basis for oligometastases and a potential for using microRNA expression to identify patients most likely to remain oligometastatic after metastasis-directed treatment

    Rhythmic radiotherapy beats down TGF-β

    No full text

    The Evolution of Radiation Therapy in Metastatic Breast Cancer: From Local Therapy to Systemic Agent

    No full text
    Radiation therapy is a mainstay of treatment in early and locally advanced breast cancer but is typically reserved for palliation of symptomatic lesions in patients with metastatic breast cancer. With new advances in the field of tumor biology and immunology, the role of radiation in the metastatic setting is evolving to harness its immune-enhancing properties. Through the release of tumor antigens, tumor DNA, and cytokines into the tumor microenvironment, radiation augments the antitumoral immune response to affect both the targeted lesion and distant sites of metastatic disease. The use of immunotherapeutics to promote antitumoral immunity has resulted in improved treatment responses in patients with metastatic disease and the combination of radiation therapy and immunotherapy has become an area of intense investigation. In this article, we will review the emerging role of radiation in the treatment of metastatic disease and discuss the current state of the science and clinical trials investigating the combination of radiation and immunotherapy
    corecore